Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus bendamustine and rituximab in newly diagnosed mantle cell lymphoma
NL-OMON52974Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Ibrutinib + bendamustine + rituximab with Placebo + bendamustine + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Oct 2013; status: active, not recruiting.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON52974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52974.